Increasing uncoupling protein-2 in pancreatic beta cells does not alter glucose-induced insulin secretion but decreases production of reactive oxygen species by Produit-Zengaffinen, N. et al.
ARTICLE
Increasing uncoupling protein-2 in pancreatic beta cells does
not alter glucose-induced insulin secretion but decreases
production of reactive oxygen species
N. Produit-Zengaffinen & N. Davis-Lameloise &
H. Perreten & D. Bécard & A. Gjinovci & P. A. Keller &
C. B. Wollheim & P. Herrera & P. Muzzin &
F. Assimacopoulos-Jeannet
Received: 13 June 2006 /Accepted: 4 September 2006 / Published online: 28 November 2006
# Springer-Verlag 2006
Abstract
Aims/hypothesis Levels of uncoupling protein-2 (UCP2)
are regulated in the pancreatic beta cells and an increase in
the protein level has been associated with mitochondrial
uncoupling and alteration in glucose-stimulated insulin
secretion. However, it is not clear whether an increase in
uncoupling protein-2 per se induces mitochondrial uncou-
pling and affects ATP generation and insulin secretion.
Materials and methods Transgenic mice with beta cell-spe-
cific overexpression of the human UCP2 gene and INS-1
cells with doxycycline-inducible overproduction of the
protein were generated and the consequences of increased
levels of UCP2 on glucose-induced insulin secretion and on
parameters reflecting mitochondrial uncoupling were
determined.
Results In transgenic mice, an increase in beta cell UCP2
protein concentration did not significantly modify plasma
glucose and insulin levels. Glucose-induced insulin secre-
tion and elevation in the ATP/ADP ratio were unaltered by
an increase in UCP2 level. In INS-1 cells, a similar increase
in UCP2 level did not modify glucose-induced insulin
secretion, cytosolic ATP and ATP/ADP ratio, or glucose
oxidation. Increased levels of UCP2 did not modify the
mitochondrial membrane potential and oxygen consump-
tion. Increased UCP2 levels decreased cytokine-induced
production of reactive oxygen species.
Conclusion/interpretation The results obtained in transgen-
ic mice and in the beta cell line do not support the
hypothesis that an increase in UCP2 protein per se
uncouples the mitochondria and decreases glucose-induced
insulin secretion. In contrast, the observation that increased
UCP2 levels decrease cytokine-induced production of
reactive oxygen species indicates a potential protective
effect of the protein on beta cells, as observed in other cell
types.
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Introduction
In the pancreatic beta cell, oxidative metabolism of glucose
and mitochondrial ATP generation are key links between
glucose sensing and insulin secretion. The production of ATP
in the mitochondria, leading to elevation in the cytosolic ATP/
ADP ratio, is the main trigger of glucose-stimulated insulin
secretion by KþATP-dependent and -independent mechanisms
(reviewed in [1]). Therefore, any modification in glucose-
induced ATP formation will have important consequences
for glucose-stimulated insulin secretion (GSIS).
In brown adipocytes, ATP generation and energy metab-
olism are modulated by the presence and activity of
uncoupling protein-1 (UCP1). Based on their similarity of
sequence, UCP2 and UCP3 were first suggested to play a
role in regulated thermogenesis [2]. Later studies demon-
strated that this may not be the case [3] and now evidence is
accumulating in favour of a role in reducing the production
of reactive oxygen species (ROS) by the mitochondria [4, 5].
Among the UCPs, UCP2 is the only uncoupling protein
present in rodent and human pancreatic beta cells [6, 7]. As
GSIS depends on ATP production, the uncoupling state that
may be induced by increased UCP2 level and/or activity is
predicted to impair insulin secretion. Indeed, several studies
have associated an increase in UCP2 with inhibition of
GSIS and indications of mitochondrial uncoupling [6–8].
An increase in UCP2 protein levels has been measured after
long-term exposure of beta cells to high concentrations of
fatty acids [9–12], with indications of mitochondrial
uncoupling. Exposure of human islets to high glucose
increases UCP2 expression, and alters GSIS [13]. Peroxi-
some proliferator-activated receptor (PPAR)α [14–16] and
PPARγ [17, 18] agonists also increase UCP2 and decrease
GSIS, except in a study in which a threefold to fourfold
increase in UCP2 level, measured after overexpression of
PPARα and RXR (retinoid X receptor), decreased neither
the mitochondrial membrane potential nor GSIS [16].
In agreement with a negative role of UCP2 in GSIS, Ucp2
knock-out mice have an increased circulating insulin level,
and in vitro their pancreatic islets secrete more insulin and
show a higher ratio of ATP/ADP in response to glucose [19].
These effects are reversed by adenoviral production of Ucp2
[20]. In addition, islets from Ucp2 knock-out mice are
protected from the long-term effects of fatty acids, suggest-
ing that UCP2 may be an important mediator of lipotoxicity
[20]. Most of these results favour the hypothesis that UCP2
negatively regulates glucose-induced changes in ATP/ADP
and insulin secretion in pancreatic beta cells.
The studies mentioned above assume that, when present,
UCP2 promotes proton leak in proportion to its level.
However, in a cellular system, UCP1 has no uncoupling
activity, unless adequately stimulated. Recent studies in
mitochondria obtained from tissues with different levels of
UCP2 or UCP3 show that these proteins exhibit uncoupling
activity only in the presence of ROS, in particular superoxide
of mitochondrial origin, with or without fatty acids [21]. As
mitochondrial ROS production is dependent on the mito-
chondrial potential, mild uncoupling could effectively
decrease ROS generation. Therefore, UCP2 activation by
ROS could be considered as a protective feed-back loop, as
suggested by studies in neurons or cardiomyocytes [22, 23].
To determine whether an increase in UCP2 per se induces
mitochondrial uncoupling and affects GSIS, we generated
transgenic mice and pancreatic beta cell lines with an increase
in UCP2 and measured GSIS, changes in ATP/ADP and
mitochondrial membrane potential. The data obtained in islets
of transgenic mice and in pancreatic beta cell lines do not
support the hypothesis that an increase in UCP2 protein
concentration partly uncouples the mitochondria and alters
glucose-stimulated insulin secretion. In agreement with the
notion that the protein acts on ROS generation, we provide
evidence that an increase in UCP2 protein concentration
decreases cytokine-induced ROS production.
Materials and methods
Generation and analysis of transgenic mice UCP2-trans-
genic mice were obtained by microinjection into fertilised
eggs of an RIP-Ucp2 cDNA construct that comprised
600 bp of the rat insulin II promoter, the entire coding
region of human UCP2 (GenBank Accession U82819) and
a rabbit β-globin intron and polyadenylation signal.
Founder animals were identified by Southern blot hybrid-
isation and PCR analysis on DNA extracted from tail
biopsies (DNAeasy tissue kit; Quiagen AG, Hilden,
Germany). The sex distribution and percentage of trans-
genic mice was 30±2.4, 26±2.2, 20±2.1, 25±2.1 for
control and transgenic males and control and transgenic
females respectively (25 litters). Male mice aged 10–
16 weeks were used for the experiments.
The mice were housed in the animal facility of the
University of Geneva Medical School. They had free access
to water and standard mouse diet. All animal procedures
were approved by the Office Vétérinaire Cantonal.
Glucose tolerance tests Glucose tolerance tests (GTTs)
were performed in mice that had fasted overnight. A
baseline blood sample was collected from the tail vein
and glucose (1.0 or 1.5 mg/g body weight) injected i.p.
Blood was collected at 15, 30, 60 and 120 min and
centrifuged, and plasma glucose was measured using
glucose oxidase (Roche Diagnostics AG, Rotkreuz, Swit-
zerland). Plasma insulin was measured at 0 and 15 min
using a kit for rat insulin radioimmunoassay (Linco
Research, St Louis, MO, USA).
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Pancreas perfusion Pancreases were perfused at 1.5
ml/min with modified KRBH (121 mmol/l NaCl, 4.8
mmol/l KCl, 1.0 mmol/l CaCl2, 1.2 mmol/l KH2PO4,
1.2 mmol/l MgSO4, 24.6 mmol/l NaHCO3, 40 g/l dextran
T-40 and 12.5 mmol/l HEPES, pH 7.4) containing 0.25%
BSA and the additions mentioned, as described in [24].
Insulin was measured by radioimmunoassay.
Islet isolation and culture, measurements of insulin secre-
tion and ATP levels Pancreatic islets were isolated by
collagenase digestion, hand-picked and cultured in RPMI
1640 medium (Invitrogen Life Technologies, Carlsbad, CA,
USA) supplemented with 10% FCS, 10 mmol/l HEPES,
100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a
humidified atmosphere containing 5% CO2. After 24 h of
culture, islets were hand-picked again, preincubated and in-
cubated in KRBH containing 0.5% fatty-acid-free BSA or
BSA–oleate prepared as described [9], and used for mea-
surement of insulin secretion and content, or ATP/ADP lev-
els. Islet insulin was extracted with cold acid–ethanol (1.5%
HCl, 75% ethanol) and measured by radioimmunoassay.
Total ATP and ADP were measured in groups of ten
islets. After glucose addition (30 min), perchloric acid
(0.6 mol/l final concentration) was added. After centrifu-
gation, the supernatant fraction was neutralised with
2.7 mol/l K2CO3 and the precipitate was removed by
centrifugation. ATP was assayed directly using a biolumi-
nescence assay kit (HSII; Roche Diagnostics AG). For
ADP measurements, ATP was first hydrolysed to AMP
using ATP sulfurylase [25]. ADP was converted to ATP
with pyruvate kinase and phosphoenolpyruvate and ATP
was measured by the same bioluminescence assay. The
same treatment was applied to the ADP standard curve.
Construction of plasmid and transfection of INS-1
cells The parental INS-1 cell line expressing the reverse
tetracycline-dependent transactivator (INS-1-r9 cells) was
kindly provided by P. Iynedjian and H. Wang. The plasmid
used for the second stable transfection was constructed by
subcloning the UCP2 cDNA isolated from a human skeletal
muscle cDNA library (GenBank accession number
U82819) into the expression vector PUHD10-3. INS-1-r9
stable transfection, clone selection and screening were as
described [26]. Four clones were obtained, and one of them
was used in the present study.
Cell culture Cells were plated (105 cells per well) into 24-
well plates and cultured under standard cell culture
conditions [9]. After 2–3 days, doxycycline (Sigma
Chemical, St Louis, MO, USA) was added for 48 h to
induce UCP2 production. Cells were incubated in the same
medium at 5 mmol/l glucose without or with doxycycline
12 h before experiments.
Insulin secretion Cells were washed, preincubated for
60 min in KRBH containing 2.8 mmol/l glucose and
0.5% BSA and incubated for 30 min with the additions
mentioned, and the insulin concentration in the medium
was determined. Total cellular insulin content, measured
after cold acid–ethanol extraction, and insulin secretion
were quantified by radioimmunoassay. DNA was measured
according to Labarca and Paigen [27].
ATP/ADP and cytosolic ATP measurements The cells were
treated as for insulin secretion, except that 10 min after
glucose addition the medium was rapidly removed and
0.75 ml of 0.6 mol/l perchloric acid was added to the cells.
The extract was processed and ATP and ADP were
measured as described previously [9].
Cytosolic ATP levels were monitored in cells infected
with the ATP-sensitive luminescent probe luciferase [28].
Twenty-four hours after the induction of UCP2 production,
the cells were infected with the specific AdRIP-Luc viral
construct. Twenty-four hours later, cytosolic ATP was
measured after the addition of 250 μmol/l beetle luciferin
(AcrosOrganics, Geel, Belgium), the luciferase substrate, as
described [28].
Western blotting Mitochondria and cytosolic fractions were
prepared from isolated islets and cultured cells using
the Mitochondria/Cytosol fractionation kit (BioVision,
Mountain View, CA, USA) according to the manufacturer’s
instructions. Proteins were measured using the Bio-Rad
protein assay (Bio-Rad Laboratories GmbH, München,
Germany), with BSA as standard.
One hundred islets of similar size, obtained from one
mouse, or the mitochondrial and cytosolic fractions of 100
islets, or 15 μg of mitochondrial proteins from INS cells,
were subjected to electrophoresis on a 12% polyacrylamide
gel, electrotransferred to Immobilon P membranes (Millipore
Corporation, Bedford, MA, USA), blocked with 2.5% Top
Block (VWR International AG, Luzern, Switzerland) in
phosphate-buffered saline and 0.1% Tween, and incubated
overnight at 4°C in the same buffer containing polyclonal
antibody to UCP2 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). After washing, the membranes were incubated
with a horseradish peroxidase-coupled IgG antibody
(Amersham Biosciences, Little Chalfont, UK) for 1 h at
room temperature. Cytochrome oxidase and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) were detected
on the same membrane, using a monoclonal antibody
against subunit IV of cytochrome oxidase (Molecular
Probes Inc. Eugene, OR, USA) or GAPDH (Chemicon
International, Temecula, CA, USA), and horseradish
peroxidase-coupled anti-mouse IgG (Santa Cruz Biotech-
nology, Santa Cruz, CA) as secondary antibody. The
resolved bands were visualised by enhanced chemilumi-
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nescence detection reagents (ECL; Amersham) and ex-
posed to Hyperfilm ECL (Amersham, UK) for 1–3 min.
Mitochondrial membrane potential and ROS formation
Mitochondrial membrane potential was measured using
rhodamine 123 (Molecular Probes). Cells in 24-well
plates were preincubated for 2 h in KRBH containing
1 mmol/l glucose, loaded with 10 μg/ml rhodamine 123
for 20 min, washed, and transferred to a thermostated
plate reader (Fluostar Optima, BMG Labtechnologies,
Offenburg, Germany). The mitochondrial membrane
potential (Δψm) was monitored with an excitation and
emission set of 485 and 525 nm, respectively. Glucose
12 mmol/l and carbonylcyanide m-chlorophenylhydrazone
(CCCP) 30 μmol/l were added successively as described
[28].
Production of ROS was measured with the ROS-
sensitive fluorescent dye CM-H2DCFDA (Molecular
Probes) after addition of recombinant human IL1β (Pepro-
Tech, Rocky Hill, NJ, USA). Cells were washed and incu-
bated in RPMI without indicator, containing 5 μmol/l
CM-H2DCFDA, for 20 min and transferred to the thermo-
stated plate reader. ROS production was monitored during
30 min with an excitation and emission set of 485 and
525 nm, respectively. ROS production was linear during the
30 min of measurement. The slope of the curve was taken
as an index of ROS production and expressed as arbitrary
units/min.
Oxygen consumption Cells were detached by incubation
with PBS, washed, resuspended in KRBH medium
containing 10% FCS and 5 mmol/l glucose, and
incubated for 15 min at 37°C. After centrifugation, they
were resuspended in the same medium containing 1%
FCS and transferred into the stirred thermostated cuvette
of a Clark-type electrode. Oxygen consumption was
measured at 12 mmol/l glucose, and 10 μmol/l oligomy-
cin and 30 μmol/l CCCP (Sigma Chemical) were added
successively. The results were standardised to DNA
concentration.
Glucose oxidation measurement Cells were detached and
preincubated with KRBH containing 2.8 mmol/l glucose
and 0.5% BSA for 60 min. Cells in suspension were
incubated with 2.8 or 12 mmol/l glucose and radiolabelled
glucose for 60 min. Glucose oxidation was measured as
14CO2 production from [U-
14C]glucose (0.1 μCi/μmol)
(Amersham). Carbon dioxide was trapped and measured as
described [9].
Statistical analysis Results are expressed as mean±SE.
ANOVA and two-tailed paired or unpaired t tests or the
Mann–Whitney test were used for statistical analysis.
Results
Transgenic mice with beta cell specific overexpression of
UCP2 Three independent founders with the RIP-hUCP2
transgene were obtained. Two of them were backcrossed for
nine or ten generations on a C57Bl/6J background and one
was used in the present study, but similar results (shown in
the Electronic supplementary material) were obtained in the
offspring of the other founder, suggesting that the pheno-
type was independent of the site of integration of the DNA
in the genome. Transgenic mice had a sixfold increase in
UCP2 production in pancreatic islets (Fig. 1a,b). Figure 1a
shows that UCP2 was found exclusively in the mitochon-
dria. No significant differences were found between control
and UCP2-overproducing mice for body weight fed and
fasting glycaemia, insulinaemia, and insulin/glucose ratio.
Plasma NEFA were slightly increased in fed but not in
fasted transgenic mice (Table 1). Pancreatic insulin content
and islet ATP and ADP contents were not significantly
different between the two groups (Table 1).
Transgenic mice with beta-cell-specific overproduction
of UCP2 had normal glucose tolerance and glucose-
stimulated insulin secretion. Intraperitoneal GTT was
performed in overnight-fasted control and transgenic mice.
Figure 2a and b shows no significant difference in the
glucose profile between the two groups, in insulin levels at
0 and 15 min, or in change in insulin concentration. To
further analyse the possible role of UCP2 overproduction in
GSIS, pancreases from control and transgenic mice were
perfused with glucose and tolbutamide. As shown in Fig. 3,
increased levels of UCP2 did not alter the insulin secretion
profiles in response to glucose and tolbutamide, while basal
insulin secretion was slightly decreased in pancreases from
transgenic mice. This decrease did not reach statistical
significance, even when using the nonparametric Mann–
Whitney test.
The possibility that UCP2 has to be activated by fatty
acids to exhibit uncoupling properties was investigated in
isolated islets from control and transgenic mice by addition
of 0.4 mmol/l BSA–oleate (Fig. 4a). Basal and GSIS were
similar in the two groups. As demonstrated by others, short-
term exposure of islets to oleate greatly amplifies GSIS
(Fig. 4a). Similar amplification was measured in islets from
control and transgenic mice, indicating that fatty acids did
not activate UCP2 or that the potent effect of fatty acids on
the fatty acid receptor GPR 40 [29] or of fatty acyl CoA on
the secretory process [30] overcame possible changes in
glucose-induced ATP production.
An increase in mitochondrial uncoupling is also
expected to result in a decreased ATP/ADP ratio.
Figure 4b shows that the ATP/ADP ratios are comparable
in control and transgenic islets at low glucose concentra-
tion, and increase similarly after glucose addition.
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Inducible overproduction of UCP2 in INS-1 cells To further
study the effects of increased levels of UCP2, the beta cell
clone INS1-r9, stably expressing the reverse tetracycline-
dependent transactivator, was transfected with the pTRE
plasmid containing UCP2 cDNA. Increasing the concen-
tration of doxycycline from 50 to 1,000 ng/ml produced a
two- to 15-fold increase in UCP2 protein levels (Fig. 1c).
Addition of 250 ng/ml doxycycline produced an increase in
UCP2 production similar to that observed in the islets of
transgenic mice (Fig. 1d). This concentration was used in
subsequent experiments.
This increase in UCP2 protein levels did not affect cell
proliferation, as measured by DNA after 3 and 6 days of
saline or doxycycline addition (data not shown).
Overproduction of UCP2 in INS-1 cells does not alter
glucose-induced insulin secretion and ATP formation
Insulin secretion was measured in response to secreta-
gogues acting via an increase in ATP (glucose, leucine) or
in a manner independent of ATP generation (tolbutamide).
Increasing UCP2 did not alter insulin secretion in response
to any of the stimulants (Fig. 5a). Higher levels of UCP2
(more than 12-fold increase) resulted in a 27% decrease in
glucose-stimulated insulin secretion, but also a 27 and 19%
decrease in secretion stimulated by tolbutamide and KCl
respectively (p<0.01 by paired t test, five independent
experiments), suggesting a non-specific effect.
Increasing UCP2 did not modify basal and glucose-
stimulated changes in ATP/ADP ratio (Fig. 5b), nor did it
modify the absolute values of ATP (200±19 and 189±
21 pmol/μg DNA, not significant) and ADP (27±4 and 25±
2 pmol/μg DNA, not significant) in control and UCP2-
overproducing cells, respectively. The glucose-induced in-
Fig. 1 Levels of UCP2 protein in pancreatic islets and INS-1 cells.
a UCP2 levels in pancreatic islets of control and RIP-UCP2 mice and
in the cytosolic and mitochondrial fraction of islets from transgenic
mice. Whole islets or cytosolic and mitochondrial proteins were
separated by SDS-PAGE and UCP2 and GAPDH were measured by
western blotting as described in the Materials and methods section.
b UCP2 was quantified by densitometric scanning and normalised to
the level of GAPDH. Mean±SE of four independent measurements;
p<0.005 between control and RIP-UCP2. c Concentration-dependent
effect of doxycycline (Doxy) on the level of UCP2 in isolated
mitochondria of INS-1 cells. For comparison, 15, 7.5, 3.75 and 1.9 ng
of recombinant UCP2 (Rec) are shown. d UCP2 was quantified by
densitometric scanning and normalised to the level of cytochrome
oxidase (cyt ox). Mean±SE of three measurements; p<0.005 between
mitochondria from non-induced cells and cells induced with 250 ng/
ml doxycycline
Table 1 Weight, plasma and pancreatic parameters of control and
RIP-UCP2 transgenic mice
Control RIP-UCP2
Weight (g) Fed 28±0.5 27.5±1.1
Fasted 25.6±0.4 25.1±1.1
Plasma Fed
Glucose (mmol/l) 8.1±0.3 8.9±0.3
Insulin (pmol/l) 136±16 131±21
Insulin/glucose ratio 17.0±2.1 14.8±2.4
NEFA (mmol/l) 0.69±0.04 0.83±0.05a
Fasted
Glucose (mmol/l) 5.6±0.6 5.6±0.3
Insulin (pmol/l) 68.8±5.1 56.8±8.6
Insulin/glucose ratio 12.2±1.2 10.3±1.5
NEFA (mmol/l) 1.1±0.08 1.1±0.06
Pancreas Insulin (μg/pancreas) 31.7±3.2 26.4±3.1
ATP (pmol/islet) 5.90±0.56 5.30±0.62
ADP (pmol/islet) 1.50±0.41 1.39±0.37
Tail vein blood samples were taken from fed and overnight fasted 10-
to 14-week-old mice. Insulin was extracted and measured in total
pancreas. ATP and ADP were determined in ten islets as described in
Materials and methods. Results are mean±SE of nine animals
(weight and plasma) or five animals (pancreas).
a p<0.05 compared with control mice
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crease in cytosolic ATP, which is more directly related to
closure of the KATP channels, was increased similarly in
control and UCP2-overproducing cells (Fig. 5c).
Increasing UCP2 does not affect oxygen consumption,
glucose oxidation and mitochondrial membrane potential
ΔΨm
 
, meaning that no uncoupling activity is induced
Oxygen consumption and glucose oxidation were measured
to test whether increased metabolism may mask putative
uncoupling activity. Control and UCP2-overproducing cells
showed no difference in oxygen consumption (Table 2).
The rate of oxygen consumption remaining after addition of
an inhibitor of ATP synthase represents proton leak by the
mitochondria, and is expected to increase with mitochon-
drial uncoupling. Table 2 shows that the addition of
oligomycin decreased oxygen consumption to the same
extent in control and UCP2-overproducing cells. The two
groups increased their O2 consumption equally after
addition of the uncoupler CCCP.
Basal glucose oxidation was similar in the control and
UCP2-overproducing cells (0.126±0.010 and 0.131±
Fig. 3 An increase in UCP2 protein concentration does not affect
insulin secretion by the perfused pancreas. Insulin release in response
to glucose (Glu 2.8, 7 and 16.7 mmol/l) and tolbutamide (100 μmol/l)
was measured in perfused pancreas from control (open squares) (n=6)
and RIP-UCP2 (filled squares) (n=4) mice, as described in the
Materials and methods section
Fig. 2 An increase in UCP2 protein concentration in pancreatic beta
cells does not affect glucose tolerance. Glucose (1.5 g/kg body weight)
was injected i.p. in overnight-fasted 12- to 14-week-old control (open
squares and bars) and RIP-UCP2 transgenic mice (filled squares
and bars). a Plasma glucose measured at 0, 15, 30, 60 and 120 min.
b Plasma insulin measured at 0 and 15 min and change in insulin
concentration (Δ). Results are mean±SE of nine animals per group
Fig. 4 Glucose-stimulated insulin secretion and changes in ATP/ADP
ratio are not affected by increased UCP2 levels. a Insulin secretion
was measured in response to glucose (Glu 4, 8, and 16 mmol/l),
without or with 0.4 mmol/l oleate (ol), and to 30 mmol/l KCl, in batch
of three isolated islets from control (open bars) and RIP-UCP2 (filled
bars) mice. Results are mean±SE of four to six measurements. b ATP/
ADP ratio was measured in isolated islets 30 min after exposure to
2 mmol/l (open bars) and 20 mmol/l (filled bars) glucose, as described
in the Materials and methods section. Results are mean±SE of seven
or eight measurements representing four or five mice in each group.
*p<0.05 compared with glucose 2 mmol/l
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0.020 nmol glucose/μg DNAxh for control and UCP2-
overproducing cells respectively, not significant) and
increased similarly when raising the glucose concentration
to 12 mmol/l (0.314±0.022 and 0.320±0.030 nmol glu-
cose/μg DNA per hour). To determine whether increased
levels of UCP2 would induce changes in ΔΨm
 
, the latter
was measured before and after glucose addition. The
hyperpolarisation induced by high glucose concentration
was similar in the two groups, as was the depolarisation
induced by 30 μmol/l CCCP (Fig. 6). Taken together with
the oxygen consumption and glucose oxidation results, this
last observation indicates that increasing UCP2 level does
not result in any sign of mitochondrial uncoupling.
Increasing UCP2 levels decrease ROS production Several
studies have suggested that UCPs may decrease ROS
generation, in particular when the production of free
radicals is increased and ‘activates’ the uncoupling protein.
Increased ROS production has been described in pancreatic
beta cells after exposure to high glucose concentrations [31,
32]. However, our control cells did not exhibit any increase
in ROS generation after short (60 min) or long (24 h)
exposure to 20 mmol/l glucose (data not shown). Mito-
chondrial ROS production in the pancreatic beta cell is also
known to increase after administration of cytokines [33].
For this reason, the possibility that increased expression of
UCP2 may act on IL1β-induced ROS production was
Fig. 5 Glucose-induced insulin secretion and changes in ATP/ADP ratio
and cytosolic ATP are not affected by high levels of UCP2 in INS-1 cells.
a Insulin secretion (expressed as percent insulin content) was measured
in response to glucose (Glu 4, and 12 mmol/l), 10 mmol/l leucine and
100 μmol/l tolbutamide (Tolb) in control (open bars) and UCP2-
overproducing cells (filled bars). The insulin content was similar in the
two groups: 25.0±2.4 and 25.1±2.6 ng/μg DNA for control and UCP2-
overproducing cells, respectively. b ATP/ADP ratios were measured
before (open bars) and 10 min after addition of 12 mmol/l glucose (final
concentration, cross-hatched bars) as described in the Materials and
methods section. All results are mean±SE of four independent experi-
ments performed in triplicate. c Cytosolic ATP levels were monitored in
control cells (open squares and circles) and in cells overproducing
UCP2 (filled squares and circles). After 8 min in the baseline condition,
cells were unstimulated (squares) or stimulated with 12 mmol/l glucose
for 10 min (circles), then ATP generation was suppressed by the
addition of 2 mmol/l NaN3. Values are mean±SE of two representative
experiments performed in quadruplicate
Table 2 UCP2 overproduction does not modify oxygen consumption
nmole O2 min
−1 μg DNA−1
Glucose
(12 mmol/l)
Oligomycin
(10 μmol/l)
CCCP
(30 μmol/l)
Control 35±7 4±1a 64±14a
UCP2 23±6 4±1a 60±13a
Cells were cultured and oxygen consumption measured as described
in the Materials and methods section. Results are mean±SE of
four independent experiments.
a p<0.05 compared with glucose 10 mmol/l
Fig. 6 The mitochondrial membrane potential is not modified by UCP2
overproduction in INS-1 cells. Mitochondrial membrane potential was
monitored in control cells (squares) and in cells overproducing UCP2
(triangles), loaded with rhodamine 123, and left without stimulation
(closed symbols) or stimulated with glucose (open symbols) and CCCP
added where indicated. The results are means of quadruplicate measure-
ments from one representative experiment performed four times. Insert
shows detail of glucose-induced hyperpolarisation of control and UCP2-
overproducing cells. The SEs have been omitted for clarity (they were
between 1.5 and 5%)
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tested. Control and UCP2-overproducing cells were ex-
posed to various concentrations of IL1β for 5 h and ROS
generation was measured. Increasing UCP2 levels resulted
in a significant decrease in IL1β-induced ROS production
(Fig. 7).
Discussion
The aim of the present study was to investigate whether an
increase in UCP2 in beta cells could per se induce
mitochondrial uncoupling and alter glucose-induced
changes in ATP/ADP ratio and insulin secretion. For the
first time, transgenic mice with pancreatic beta-cell-specific
increase in UCP2 protein were generated. These mice had
no particular phenotype; their plasma insulin and glucose
levels were not significantly modified in the fed or in the
fasted states or during a GTT. Glucose-induced ATP
generation and insulin secretion were comparable in control
and transgenic mice, suggesting that an increase in UCP2
per se is not sufficient to uncouple beta cells and decrease
ATP production and insulin secretion.
Our results in transgenic mice are in contrast to those
obtained in UCP2−/− mice, which exhibit a clear increase in
basal and glucose-induced ATP level and insulin secretion
[19]. The difference in ATP/ADP ratio and mitochondrial
membrane potential measured in islets of wild-type and
UCP2−/− mice implies that even in the basal state, i.e. in the
absence of activator, UCP2 is active and promotes proton
leak in control mice. This is in contrast with a general
consensus that, in a cell, a UCP has an uncoupling activity
only in the presence of specific activators [34].
It is difficult to explain why UCP2 ablation has such
important consequences for insulin secretion, whereas its
increase has no effect. One important feature of overall
ablation of UCP2 in mice is a slightly elevated plasma level of
inflammatory cytokines such as IFN-γ and TNF-α and an
increased generation of nitric oxide and cytokines upon
antigenic challenge [35]. One would expect that this constant
low inflammatory state reduces beta cell viability. However,
recent data obtained in rat beta cells demonstrate that a
transient and moderate increase in NF-κB (nuclear factor-
κB) activity improves beta cell function and insulin secretion
[36]. Furthermore, attenuation of NF-κB activation in
transgenic mice impairs GSIS and decreases the expression
of genes involved in glucose metabolism and insulin
exocytosis [37]. Taken together, these data indicate that
moderate activity of NF-κB could be beneficial to the beta
cell. An alternative explanation for the lack of phenotype of
mice with a beta cell specific increase in UCP2 could be that
the ‘basal’ level of UCP2 present in wild-type mice may be
sufficient to trigger a full effect of the protein. Indeed, in
Fig. 7 in [20], overproduction of UCP2 in pancreatic islets of
UCP2−/− mice resulted in a level of UCP2 above that
observed in wild-type mice, but GSIS was similar to that
measured in islets from wild-type mice, suggesting that the
excess UCP2 had no further effect compared with the control
situation. Alternatively, the genetic background could play a
role, although the studies using UCP2-/- mice, as the present
study, used C57Bl/6J mice [38].
The consequences of increased levels of UCP2 in the
beta cell line INS-1 confirmed and extended the results
obtained in islets. Increased levels of UCP2 similar to those
measured in transgenic mice did not alter GSIS or induce
any sign of uncoupling. The data are in agreement with the
observation that the threefold to fourfold increase in UCP2
measured in INS-1E cells with high levels of PPARα and
RXR did not modify ΔΨμ or GSIS [16], and with the
notion that UCPs have to be activated to exhibit uncoupling
activities [34]. The possibility remains, however, that
increasing expression of UCP2 induced slight changes in
mitochondrial potential that cannot be detected by the
methods used.
In previous studies, the role of UCP2 in pancreatic beta
cells was mostly studied after supraphysiological produc-
tion of the protein. The consequences of such high levels of
UCP2 may, however, reflect an uncoupling artefact caused
by disruption of the mitochondrial membrane integrity, and
not the physiological role of the protein [3]. In the present
study, overproduction of UCP2 by more than tenfold also
decreased insulin secretion. Indeed, there is now evidence
in several cell types that a moderate increase in UCP2 [34,
39] or UCP3 [40, 41] levels does not induce any sign of
mitochondrial uncoupling. The results of the present study
demonstrate that this could also be the case for pancreatic
Fig. 7 Cytokine-induced ROS production is decreased by UCP2
overproduction. ROS production was assessed in control (open bars)
and UCP2-overproducing cells (filled bars) using the fluorescent
marker CM-H2-DCFDA. ROS production was measured 5 h after
addition of 0, 62, 125 or 250 pg/ml IL1β, as described in the Materials
and methods section. Mean±SE of triplicate measurements in one
representative experiment performed three times. AU arbitrary units.
*p<0.05 compared with control cells
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beta cells. This lack of effect could be due to the absence or
limited levels of an endogenous activator or suggest that
UCP2 has no role in proton leak.
As an increase in UCP2 did not uncouple the beta cell or
modify GSIS, the possible role of the protein in ROS
production was examined after short or long exposure to
high glucose concentrations. No increase in ROS genera-
tion was measured in either condition. These data are in
agreement with recent investigations demonstrating that
high glucose concentrations do not increase but rather
decrease ROS generation in rat pancreatic beta cells [42].
Mitochondrial ROS generation has also been reported in
beta cells after cytokine exposure [33]. Our results show
that increasing UCP2 protein levels promoted a decrease in
IL1-β-induced ROS production. These data can be related
to observations in endothelial cells after high glucose or
angiotensin II addition [43], or cardiomyocytes exposed to
oxidative stress [23], in which an increase in UCP2
prevented ROS generation. The mechanism of action of
UCP2 and the exact nature of the ROS induced by
cytokines is presently being investigated. In addition to
preventing ROS production, increasing UCP2 also attenu-
ated cytokine-induced cell death [44].
In conclusion, the results of the present study demon-
strate, in two independent models, that an increase in UCP2
protein per se does not induce any sign of mitochondrial
uncoupling or alteration in glucose-induced mitochondrial
hyperpolarisation, ATP/ADP ratio and insulin secretion. In
contrast, increases in UCP2 protein decreased cytokine-
induced ROS generation, an observation in agreement with
the role described for UCP2 in other cell types [23, 43].
These data indicate that the protective effect of UCP2 on
ROS production may overcome its potential deleterious
effects on glucose-stimulated insulin secretion.
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